Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026

The Phase 1b poster covers a single-dose study of ATTO-1310 that compares treatment with a placebo.

Rhea-AI Summary

Attovia Therapeutics (ATTO) will present four posters on ATTO-1310 and ATTO-2306 at two dermatology conferences in 2026.

At EADV in Vienna, September 30–October 3, two ATTO-1310 posters will cover Phase 1a safety and pharmacology data from healthy adults and research into IL-31 levels across itchy skin diseases. At FCD in Las Vegas, October 8–11, one poster will cover interim Phase 1b ATTO-1310 results in patients with high-itch atopic dermatitis or chronic pruritus, while another will present preclinical ATTO-2306 data. The posters will be available on Attovia's website after each conference.

Key Terms

pharmacokinetics, pharmacodynamics, placebo-controlled, bispecific antibody

4 terms

pharmacokinetics medical

"Safety, Pharmacokinetics, and Pharmacodynamics of ATTO-1310"

Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.

pharmacodynamics medical

"Safety, Pharmacokinetics, and Pharmacodynamics of ATTO-1310"

Pharmacodynamics is how a drug actually affects the body — the strength, type and duration of its effects and the relationship between dose and response. Think of it like how turning a thermostat changes room temperature: it shows what the drug does and how much is needed to get the desired effect. Investors care because these properties drive clinical success, dosing convenience, safety profile and competitive advantage, all of which influence commercial potential and regulatory approval.

placebo-controlled medical

"a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

bispecific antibody medical

"a Long-Acting Bispecific Antibody Targeting IL-13 and IL-31"

A bispecific antibody is a specially designed protein that can attach to two different targets at the same time. Think of it as a custom-made connector that brings two things together—such as a disease cell and an immune system component—helping the body fight illnesses more effectively. For investors, understanding bispecific antibodies is important because they represent innovative therapies that could lead to new treatments and potentially lucrative market opportunities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN CARLOS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that it will present new clinical, translational, and preclinical data across its pipeline at the European Academy of Dermatology and Venereology (EADV) Congress 2026 and the Fall Clinical Dermatology Conference (FCD) 2026.

Attovia will present four posters: three on ATTO-1310, a next generation anti-IL-31 ATTOBODY-based therapeutic, and one on ATTO-2306, a novel long-acting anti-IL-31 and IL-13 bispecific. The ATTO-1310 posters will highlight Phase 1a data in healthy volunteers, translational data advancing the understanding of IL-31 across pruritic skin diseases, and interim Phase 1b data in patients with high-itch atopic dermatitis (AD) or with chronic pruritus. The ATTO-2306 poster will feature new preclinical data.

The EADV Congress 2026 will take place September 30 - October 3, 2026 in Vienna, Austria and FCD 2026 will take place on October 8-11, 2026 in Las Vegas, Nevada. Presentation details are below.

ATTO-1310

• EADV 2026 Poster Presentations
  • Title: Safety, Pharmacokinetics, and Pharmacodynamics of ATTO-1310, a Novel Anti-IL-31 ATTOBODY-Fc Fusion Protein, in Healthy Adults (Abstract: AS-1248)
  • Title: Ultra-Sensitive Detection of Circulating IL-31 Reveals Elevated Levels Across Pruritic Skin Diseases (Abstract: AS-3150)
• FCD 2026 Poster Presentation
  • Title: Efficacy and Safety of a Single Dose of ATTO-1310, a Novel Anti-IL-31 ATTOBODY-Fc Fusion Protein: Interim Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study in Patients with Atopic Dermatitis or with Chronic Pruritus
    
    

ATTO-2306

• FCD 2026 Poster Presentation
  • Title: Preclinical Characterization of ATTO-2306, a Long-Acting Bispecific Antibody Targeting IL-13 and IL-31 for Type 2 Inflammatory Skin Diseases
    
    

Following each congress, the posters will be available on the Publications page of the Attovia website at https://www.attovia.com.

About Attovia Therapeutics, Inc.
Attovia™ is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need. All of its product candidates have been internally discovered using its ATTOBODY™ biparatopic biologics platform. Attovia’s ATTOBODY platform uses an evolution-driven, high-throughput process that allows for rapid discovery and creation of a high diversity of potential product candidates.

Attovia’s lead programs include ATTO-1310, an anti-IL-31 ATTOBODY-based therapeutic in clinical development for chronic pruritic diseases; ATTO-2306, a long-acting bispecific antibody targeting IL-31 and IL-13 in IND-enabling studies for atopic dermatitis and other immune-mediated skin diseases; and ATTO-1091, a trispecific antibody targeting TL1A, IL-23p19, and integrin α4β7 in IND-enabling studies for inflammatory bowel disease. Attovia’s other programs include highly innovative conditional ‘AND’ gated bispecific immune cell survival blockers and multispecifics.

Investor and Media Contact

Attovia Therapeutics
ir@attovia.com

PJ Kelleher
LifeSci Advisors LLC
617-430-7579
pkelleher@lifesciadvisors.com